We are live on
!
Find out more
DY
Dowling & Yahnke Portfolio holdings
AUM
$2.15B
Turnover
6.98%
1-Year Est. Return
10.82%
This Fund
S&P 500
This Quarter
Est. Return
+0.06%
1 Year Est. Return
-10.82%
3 Year Est. Return
+34.82%
5 Year Est. Return
+71.23%
10 Year Est. Return
–
AUM
$760M
AUM Growth
-$14.8M
(-1.9%)
Cap. Flow
-$10.8M
Cap. Flow
% of AUM
-1.43%
Top 10 Holdings %
Top 10 Hldgs %
26.66%
Holding
282
New
10
Increased
87
Reduced
123
Closed
24
Avg Time Held
1.1
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$540K |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$414K |
| 3 |
Tesla
TSLA
|
+$277K |
| 4 |
OREX
Orexigen Therapeutics, Inc.
OREX
|
+$277K |
| 5 |
Calavo Growers
CVGW
|
+$224K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$850K |
| 2 |
Air Products & Chemicals
APD
|
+$536K |
| 3 |
DuPont de Nemours
DD
|
+$520K |
| 4 |
Waste Management
WM
|
+$482K |
| 5 |
Genuine Parts
GPC
|
+$458K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 20.05% |
| 2 | Healthcare | 13.83% |
| 3 | Consumer Staples | 13.13% |
| 4 | Technology | 12.13% |
| 5 | Financials | 10.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
226
Acacia Research
ACTG
$415M
| $251K | 0.03% |
16,190
| – | – |
2013 Q2
5 quarters
|
|
227
Edgewell Personal Care
EPC
$1.32B
| $249K | 0.03% |
2,725
| – | – |
2013 Q4
3 quarters
|
|
228
Novartis
NVS
$287B
| $240K | 0.03% |
2,850
-175
| -6% | -$14.2K |
2014 Q1
2 quarters
|
|
229
SPDR Gold Trust
GLD
$142B
| $239K | 0.03% |
2,060
-125
| -6% | -$15.4K |
2013 Q2
5 quarters
|
|
230
State Street Energy Select Sector SPDR ETF
XLE
$43.2B
| $239K | 0.03% |
5,274
+400
| +8% | +$19.4K |
2013 Q3
4 quarters
|
|
231
Agilent Technologies
A
$49.4B
| $238K | 0.03% |
5,834
-182
| -3% | -$7.43K |
2013 Q3
4 quarters
|
|
232
Worthington Enterprises
WOR
$3.19B
| $235K | 0.03% |
10,223
| – | – |
2013 Q2
5 quarters
|
|
233
DexCom
DXCM
$33.2B
| $230K | 0.03% |
23,048
| – | – |
2014 Q1
2 quarters
|
|
|
AGN
234
DELISTED
Allergan plc
AGN
| $229K | 0.03% |
949
| – | – |
2014 Q2
1 quarter
|
|
235
iShares US Consumer Discretionary ETF
IYC
$1.23B
| $227K | 0.03% |
7,300
-200
| -3% | -$6.26K |
2013 Q3
4 quarters
|
|
236
Acadia Pharmaceuticals
ACAD
$3.33B
| $223K | 0.03% |
9,000
-1,000
| -10% | -$23.4K |
2013 Q2
5 quarters
|
|
|
NBL
237
DELISTED
Noble Energy, Inc.
NBL
| $222K | 0.03% |
3,250
| – | – |
2013 Q2
5 quarters
|
|
238
Western Alliance Bancorporation
WAL
$8.28B
| $221K | 0.03% |
9,246
| – | – |
2013 Q4
3 quarters
|
|
|
OREX
239
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $220K | 0.03% |
+5,160
| New | +$277K |
2014 Q3
0 quarters
|
|
240
iShares Russell 1000 Value ETF
IWD
$84B
| $219K | 0.03% |
+2,189
| New | +$222K |
2014 Q3
0 quarters
|
|
241
iShares S&P Mid-Cap 400 Growth ETF
IJK
$10.5B
| $215K | 0.03% |
+5,668
| New | +$220K |
2014 Q3
0 quarters
|
|
|
KMP
242
DELISTED
KINDER MORGAN ENER PNTRS L.P.
KMP
| $207K | 0.03% |
+2,220
| New | +$198K |
2014 Q3
0 quarters
|
|
243
Ameresco
AMRC
$1.08B
| $186K | 0.02% |
27,200
-9,000
| -25% | -$67.9K |
2014 Q1
2 quarters
|
|
244
InfuSystem Holdings
INFU
$274M
| $152K | 0.02% |
48,350
-66,650
| -58% | -$188K |
2013 Q2
5 quarters
|
|
245
Tandem Diabetes Care
TNDM
$1.17B
| $136K | 0.02% |
1,014
| – | – |
2014 Q2
1 quarter
|
|
|
DYSL
246
DELISTED
Dynasil Corporation of America
DYSL
| $120K | 0.02% |
77,432
| – | – |
2013 Q2
5 quarters
|
|
|
ALU
247
DELISTED
Alcatel-Lucent
ALU
| $42K | 0.01% |
+13,832
| New | +$47.2K |
2014 Q3
0 quarters
|
|
|
LQMT
248
DELISTED
LIQUIDMETAL TECHNOLOGIES INC
LQMT
| $42K | 0.01% |
214,500
| – | – |
2013 Q2
5 quarters
|
|
|
ELON
249
DELISTED
Echelon Corp
ELON
| $41K | 0.01% |
+2,000
| New | +$45.1K |
2014 Q3
0 quarters
|
|
250
Arthur J. Gallagher & Co
AJG
$64.5B
| – | – |
-9,355
| Closed | -$436K | – |
|
Similar funds
AC
APA
IC
SCA
ACM
W
Dowling & Yahnke's Q3 2014 Portfolio in Review
As of Q3 2014, Dowling & Yahnke held 282 positions worth $760M, down 1.9% from $774M the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Dowling & Yahnke's Q3 2014 filing shows 10 new, 87 increased, 123 reduced and 24 closed positions. Its largest new stake was Tesla: 16,800 shares worth $272K. The largest sale was Intel, an estimated $850K.
By sector, the portfolio is most concentrated in Miscellaneous at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Consumer Staples.
- Dowling & Yahnke's largest Q3 2014 buy was Tesla: 16,800 shares worth $272K.
- Dowling & Yahnke added most to Qualcomm in Q3 2014, an estimated $540K increase.
- Dowling & Yahnke's biggest Q3 2014 reduction was Intel, cutting an estimated $850K.
- Dowling & Yahnke fully exited Air Products & Chemicals in Q3 2014, selling an estimated $536K.
- Dowling & Yahnke's ten largest holdings make up 27% of its $760M portfolio in Q3 2014.
- Dowling & Yahnke opened 10 new positions and closed 24 in Q3 2014.
- Dowling & Yahnke's portfolio value fell 1.9% quarter-over-quarter to $760M.
Based on Dowling & Yahnke's 13F filing for Q3 2014, filed 22 Oct 2014.